Threading an Antigen Through the Eye of Patentability to Sew Up Profits: Biogen Inc v Medeva plc

Research output: Contribution to journalArticle

Abstract

Criticism of HL ruling that patent for hepatitis B virus antigen was invalid because claim was too broad, insufficiently inventive and unsupported by disclosure.
Original languageEnglish
Pages (from-to)301-310
Number of pages10
JournalInternational Journal of Biosciences and the Law
Volume1
Issue number3
Publication statusPublished - 1 Jan 1997
Externally publishedYes

Fingerprint Dive into the research topics of 'Threading an Antigen Through the Eye of Patentability to Sew Up Profits: Biogen Inc v Medeva plc'. Together they form a unique fingerprint.

  • Cite this